JW Pharmaceutical will increase its R&D competitiveness by utilizing an artificial intelligence solution.
The pharmaceutical firm said on May 2 that it signed a memorandum of understanding (MOU) with Syntekabio on joint research using an artificial intelligence (AI) platform based on genome big data .
According to the agreement, JW Pharmaceutical will increase the efficiency of research and development by discovering biomarkers of new drug candidates using drug reactivity prediction technology of the Personal Genome Map Platform (PMAP) of Syntekabio.
In addition, the company will apply Syntekabio's platform technology to the field of regenerative medicine for the treatment of neurological diseases, and research on expanding indications for drugs being developed and sold.
Along with this, we intend to broaden the scope of cooperation to the field of precision medicine such as nutritional supply in the body, comprehensive nutrition infusion system related to immunization promotion, and development of new concept diagnosis reagent.
Syntekabio is a research institute-type company of the Korea Electronics and Telecommunication Research Institute (ETRI). The company discovered genetic biomarkers and developed an anticancer drug response prediction platformby combininggenomic big data and insilico technology and is currently studying patient stratification. The company has drawn up a plan to build the largest cloud-based genome big data platform in Korea via collaboration with Naver Cloud and expects the plan to give momentum to AI-based new drug development.